
CABA Valuation
Cabaletta Bio Inc
- Overview
- Forecast
- Valuation
- Earnings
CABA Relative Valuation
CABA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CABA is overvalued; if below, it's undervalued.
Historical Valuation
Cabaletta Bio Inc (CABA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.30. The fair price of Cabaletta Bio Inc (CABA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:1.55
Fair
-0.85
PE
1Y
3Y
5Y
Trailing
Forward
0.11
EV/EBITDA
Cabaletta Bio Inc. (CABA) has a current EV/EBITDA of 0.11. The 5-year average EV/EBITDA is -1.95. The thresholds are as follows: Strongly Undervalued below -7.02, Undervalued between -7.02 and -4.48, Fairly Valued between 0.59 and -4.48, Overvalued between 0.59 and 3.13, and Strongly Overvalued above 3.13. The current Forward EV/EBITDA of 0.11 falls within the Historic Trend Line -Fairly Valued range.
0.11
EV/EBIT
Cabaletta Bio Inc. (CABA) has a current EV/EBIT of 0.11. The 5-year average EV/EBIT is -2.04. The thresholds are as follows: Strongly Undervalued below -6.96, Undervalued between -6.96 and -4.50, Fairly Valued between 0.43 and -4.50, Overvalued between 0.43 and 2.89, and Strongly Overvalued above 2.89. The current Forward EV/EBIT of 0.11 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Cabaletta Bio Inc. (CABA) has a current PS of 0.00. The 5-year average PS is 0.63. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -2.20, Fairly Valued between 3.45 and -2.20, Overvalued between 3.45 and 6.28, and Strongly Overvalued above 6.28. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.01
P/OCF
Cabaletta Bio Inc. (CABA) has a current P/OCF of -1.01. The 5-year average P/OCF is -4.11. The thresholds are as follows: Strongly Undervalued below -11.44, Undervalued between -11.44 and -7.78, Fairly Valued between -0.44 and -7.78, Overvalued between -0.44 and 3.22, and Strongly Overvalued above 3.22. The current Forward P/OCF of -1.01 falls within the Historic Trend Line -Fairly Valued range.
-0.94
P/FCF
Cabaletta Bio Inc. (CABA) has a current P/FCF of -0.94. The 5-year average P/FCF is -5.53. The thresholds are as follows: Strongly Undervalued below -14.30, Undervalued between -14.30 and -9.91, Fairly Valued between -1.14 and -9.91, Overvalued between -1.14 and 3.25, and Strongly Overvalued above 3.25. The current Forward P/FCF of -0.94 falls within the Overvalued range.
Cabaletta Bio Inc (CABA) has a current Price-to-Book (P/B) ratio of 0.83. Compared to its 3-year average P/B ratio of 2.20 , the current P/B ratio is approximately -62.22% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about -59.40% higher. Cabaletta Bio Inc (CABA) has a Forward Free Cash Flow (FCF) yield of approximately -71.71%. Compared to its 3-year average FCF yield of -45.25%, the current FCF yield is approximately 58.45% lower. Relative to its 5-year average FCF yield of -41.24% , the current FCF yield is about 73.88% lower.
0.81
P/B
Median3y
2.20
Median5y
2.04
-71.71
FCF Yield
Median3y
-45.25
Median5y
-41.24
Competitors Valuation Multiple
The average P/S ratio for CABA's competitors is 2.04, providing a benchmark for relative valuation. Cabaletta Bio Inc Corp (CABA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CABA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CABA in the past 1 year is driven by Unknown.
People Also Watch

ECBK
ECB Bancorp Inc
17.220
USD
+0.58%

LPTH
LightPath Technologies Inc
4.920
USD
+9.33%

NNBR
NN Inc
2.420
USD
-0.82%

DIBS
1stdibs.Com Inc
2.680
USD
+2.29%

NEON
Neonode Inc
23.430
USD
-9.05%

VEEA
Veea Inc
0.645
USD
+0.78%

PDCC
Pearl Diver Credit Company Inc
16.770
USD
+3.81%

OPTT
Ocean Power Technologies Inc
0.516
USD
+1.18%

CEP
Cantor Equity Partners Inc
23.560
USD
+0.77%
FAQ

Is Cabaletta Bio Inc (CABA) currently overvalued or undervalued?
Cabaletta Bio Inc (CABA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.30. The fair price of Cabaletta Bio Inc (CABA) is between to according to relative valuation methord.

What is Cabaletta Bio Inc (CABA) fair value?

How does CABA's valuation metrics compare to the industry average?

What is the current P/B ratio for Cabaletta Bio Inc (CABA) as of Aug 27 2025?

What is the current FCF Yield for Cabaletta Bio Inc (CABA) as of Aug 27 2025?

What is the current Forward P/E ratio for Cabaletta Bio Inc (CABA) as of Aug 27 2025?
